All In Biotech

Drug Trial Radar · NCT07493512

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

A Phase 1b, Open-label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 28, 2026

Primary completion

Jul 30, 2030

Study completion Jul 30, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

  • XaluritamigDrug

    Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to 3.6 Year

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • United States Oncology Regulatory Affairs Corporate Office

    Denver, Colorado · Recruiting

  • US Oncology Research Investigational Products Center

    Denver, Colorado · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Oncology Hematology Care Incorporated

    Cincinnati, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Sanford Oncology Clinic and Pharmacy

    Sioux Falls, South Dakota · Recruiting

  • Sarah Cannon Research Institute Oncology Partners

    Nashville, Tennessee · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Next Oncology - Dallas

    Irving, Texas · Recruiting

  • Virginia Oncology Associates - Hampton

    Norfolk, Virginia · Recruiting

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Monash Medical Centre

    Clayton, Victoria, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.